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Equine infectious anemia virus (EIAV) is a macrophage-tropic lentivirus that persistently infects horses and causes a disease that is
characterized by periodic episodes of fever, thrombocytopenia, and viremia. EIAVencodes only four regulatory/accessory genes, (tat, rev, ttm, and
S2) and is the least genetically complex of all known lentiviruses. We sought to determine the role of the EIAV S2 accessory gene of EIAV by
introducing mutations that would prevent S2 expression on the p19/wenv17 infectious molecular clone. Virus derived from the p19/wenv17
molecular clone is highly virulent and routinely fatal when given in high doses (J. Virol. 72 (1998) 483). In contrast, an S2 deletion mutant on the
p19/wenv17 background is unable to induce acute disease and plasma virus loads were reduced by 2.5 to 4.0 logs at 15 days post-infection. The
S2 deleted virus failed to produce any detectable clinical signs during a 5-month observation period. These results demonstrate that S2 gene
expression is essential for disease expression of EIAV.
© 2006 Elsevier Inc. All rights reserved.Keywords: Equine infectious anemia virus; Viral pathogenesis; S2 accessory gene; Accessory gene deletion; Pathogenesis mutantIntroduction
Equine infectious anemia virus is a persistent pathogen of
equines that causes both acute and chronic disease. While most
other lentivirus infections result in a slow time course of disease
progression, EIAV infection results in a rapid disease progres-
sion with acute and chronic disease episodes interspersed with
periods of no disease expression or inapparent phase (Issel and
Coggins, 1979). This rapid disease progression makes EIAV a⁎ Corresponding author. Fax: +1 919 515 4237.
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doi:10.1016/j.virol.2005.12.041useful model to study lentiviral pathogenesis. Typically, within
1 to 4 weeks post-infection, the infected horse undergoes an
acute disease phase during which time plasma viremia levels are
increased and thrombocytopenia occurs. The infected horse
may also have a fever, anorexia, or central nervous system
depression. It has been shown that, during infection, high
plasma viral RNA levels (viral load) correlate with viremic
episodes and disease symptoms (Kono, 1969; Kono et al., 1973;
Langemeier et al., 1996). Following the acute disease phase is
the inapparent phase. During this phase, the horse displays no
overt signs of disease but still may act as a reservoir for disease
due to the presence of a low titer viremia. This low titer viremia
also makes it difficult to detect circulating virus (Kim and
Casey, 1994; Langemeier et al., 1996). The inapparent phase is
at least partially controlled by specific immune responses since
it has been shown that immunosuppression can lead to disease
episodes (Kono et al., 1975; Tumas et al., 1994). The inapparent
phase is periodically interrupted by episodes of chronic disease
expression that are associated with the emergence of new virus
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1986).
EIAV has a genetically simple genome compared to other
lentiviruses containing gag, pol, and env genes and encoding
the accessory/regulatory proteins, Tat, Rev, Ttm, and S2. The
EIAV Tat protein functions in transactivation of transcription
of the long terminal repeat (LTR) region in order to activate
viral gene expression (Dorn et al., 1990; Noiman et al., 1990).
Rev is responsible for temporal regulation of viral gene
expression. This occurs through post-transcriptional transacti-
vation of nuclear exported spliced and unspliced viral
transcripts through direct interaction with the Rev-responsive
elements (RRE) (Martanaro et al., 1994). These functions
make it likely that both Tat and Rev are essential for viral gene
expression. Ttm is a protein of unknown function that is
encoded by the first exon of tat and a portion of the 3′-
terminus of the transmembrane protein-coding region (Beisel
et al., 1993).
The S2 protein is approximately 7 kDa in size and is coded
for in the S2 ORF. The S2 gene is found in all known EIAV
proviral sequences (Schiltz et al., 1992). The cDNA sequence
of S2 is highly conserved among all published viral variants in
vivo during persistent infection (Li et al., 2000). The
translational initiation site for S2 is located between pol and
env gene regions, immediately following the second exon of
Tat (Li et al., 1998). The S2 ORF also overlaps the amino
terminal region of env. Transcription of S2 presumably occurs
by ribosomal leaky scanning of a tricistronic mRNA message
encoding Tat, S2, and Env or from the bicistronic transcript
encoding S2 and Env (Schiltz et al., 1992). S2 is not necessary
for viral infectivity of equine blood monocytes or replication
in vitro (Li et al., 1998). Additionally, investigators have
reported that S2 does not appear to affect the transition of
latently EIAV-infected monocytes to differentiated productive-
ly infected macrophages (Li et al., 1998). Recently, an in vivo
experiment using a molecular clone containing a mutated S2
coding region resulted in reduced viral RNA levels compared
to parental virus (Li et al., 2000). However, this study failed to
directly address the role of S2 in acute disease expression as
the parental molecular clone, EIAVUK, failed to generate either
febrile episodes or clinical thromobocytopenia in the study (Li
et al., 2000). We have previously described an infectious
molecular clone (p19/wenv17), which is highly virulent and
routinely fatal when given in high doses (Payne et al., 1998).Fig. 1. Amino acid alignment of the S2 proteins of six North American and four Asi
strains of virus are indicated in red and include an N-myristylation site, a casein kina
protein kinase C phosphorylation sites. Some virus strains have more than the two pre
(*). (For interpretation of the references to colour in this figure legend, the reader isOur goal was to rigorously test the in vivo role of the S2 gene
of EIAV by introducing mutations that would prevent S2
expression on the p19/wenv17 infectious molecular clone.
This study provides compelling evidence for a direct role of
S2 gene expression in EIAV-induced acute disease episodes in
ponies.
Results and discussion
S2 expression is dependent on the first methionine residue for
expression
The S2 open reading frame from most sequenced EIAV
strains predicts two methionine residues near the amino
terminus of the full-length protein (Fig. 1). It has been
previously demonstrated by amino acid sequence analysis that
the first methionine is utilized for initiation of protein
synthesis in an in vitro translation system (Schiltz et al.,
1992). However, we wished to determine if the second
methionine codon, 16 codons downstream of the first
methionine, could be utilized as an alternative site for
initiation of S2 protein synthesis, producing a truncated form
of S2. Since a truncated form of S2 protein that could be
initiated at the second methionine codon would contain most
of the highly conserved motifs (all but the predicted N-
myristylation site) for this protein, we felt it was important to
determine if downstream initiation of translation was occur-
ring. Premature termination codons were introduced on the
infectious, avirulent, pER molecular clone. pER was initially
used as a background for analysis of S2 function as virus
derived from pER has been shown to replicate in a wide
variety of cell types (Perry et al., 1992), making this vector
ideal for initial S2 mutagenesis experiments. S2 mutants were
constructed to ensure the authentic expression of the over-
lapping env gene. The first S2 mutation (mutant p14) was
located at nucleotide position 5301, 5 amino acids downstream
of the predicted methionine initiation codon for the S2 protein
(Fig. 2A). The second mutation (mutant p22) was located at
nucleotide position 5323 (amino acid 13 of S2), which is also
downstream of the envelope initiation codon (Fig. 2A). DNA
from each of the S2 mutants was used to transfect Cf2Th cells.
Supernatants were collected and assayed for RT activity, and
equivalent amounts (50,000 cpm) were then used to infect
equine macrophage cells.an strains of equine infectious anemia virus. The motifs that are conserved in all
se 2 phosphorylation site, an SH3 (src homology region 3)-binding site, and two
dicted PKC sites, but all strains have the two PKC sites indicated with an asterisk
referred to the web version of this article.)
Fig. 2. Introduction of two independent termination codons determines that the
first methionine residue is essential for S2 expression. (A) Schematic
representation of the amino acid sequence of the EIAV S2 open reading
frame (ORF) and the overlapping N-terminal region of the gp90 envelope
protein. The S2 mutants are listed below pER. The asterisk (*) indicates the
location of the termination codon in the S2 ORF of each mutant, the dashes
represent identity with the pER amino acid at that position. A lysine at
position 5301 and a serine at position 5323 were converted to termination
codons by site-directed mutagenesis. (B) Analysis of viral proteins by
immunoprecipitation of radiolabeled macrophage cell lysates from mock-
infected macrophages (lanes A–C), macrophages infected with the S2 mutant
p14 (lanes D–F), p22 (lanes G–I), or pER (lanes J–L). Immunoprecipitation
with pre-immune guinea pig serum (lanes A, D, G, and J), guinea pig S2
antiserum (lanes B, E, H, and K), or rabbit EIAV antiserum (lanes C, F, I, and
L). The 9.5 kDa S2 protein identified in the pER-infected macrophages with
the S2 antisera is indicated (lane K). Two additional proteins (16 kDa and 20
kDa) identified in the p14-infected cells with S2 antiserum (lane E) could not
be detected in subsequent experiments. Viral gag proteins (p26 and p15) are
indicated on the right.
Fig. 3. Site-directed mutagenesis of the S2 gene of p19/wenv17 infectious
molecular clone. The upstream primer 5′-GATTAAGGGATTATTGGTAAAG-
GGGTAACATGG-3′ and the downstream oligonucleotide 5′-CCATGTTA-
CCCCTTTACCAATAATCCCTTAATC-3′ were used to incorporate the desired
mutations using the infectious molecular clone p19/wenv17 to generate p19/
wenv17ΔS2. The arrows demonstrate the positions of the two deletions mutants
introduced, as well as the disruption of the initiation codon, and the noncoding
change. None of the generated mutants disrupted the Env start site.
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macrophages (7 dpi) were detected by immunoprecipitation
using a guinea pig antiserum to recombinant S2 protein (anti-
S2), EIAV polyclonal immune horse serum (anti-EIAV), or
mock (Fig. 2B). The p26 core protein and the p15 matrix protein
were immunoprecipitated from the pER-infected macrophage
lysates using anti-EIAV and were used as internal protein
controls (Fig. 2B, lane L). The S2 antiserum precipitated a 9.5
kDa S2 protein from the pER-infected macrophages (Fig. 2B,
lane K). The S2 protein was not precipitated from the mock-
infected cells or either of the S2-mutant-infected cells (Fig. 2B,
lanes A–I). In the p14 macrophage-infected cell lysate, two
additional proteins of approximately 16 kDa and 20 kDa were
detected with the S2 antiserum (Fig. 2B, lane E). However,
when this cell lysate was reprecipitated with the S2 antiserum,
the proteins were not detected, indicating that they may have
been artifacts in the first reaction (data not shown). Since S2
expression is not evident in the S2-mutant-infected cells and is
present in pER-infected cells, we conclude that the first
methionine residue is responsible for initiating S2 expression.
The inability of the methionine at position 16 to serve as an
efficient initiator of a truncated S2 protein in cultured cellssuggests that it is likely that only the first methionine residue is
used in vivo.
Equivalent amounts (50,000 cpm of RT activity) of virus
from pER and S2 mutants p14 and p22 were used to infect
equine dermal cells and equine macrophage cells to generate
viral replication curves as shown in Figs. 4A and B. Viruses
derived from p14 and p22 were able to replicate in both
equine macrophages and equine dermal cells although with
somewhat delayed kinetics as compared to virus derived from
the parental pER plasmid. Replication levels of the S2 mutants
in both macrophages and ED cells reached approximately 50
to 75% the level of the parental virus by 12 dpi. In
persistently infected ED cells, the virus levels (RT activity)
increased to approximately parental levels by 3 weeks post-
infection. These results confirm a previous report that S2 is
not strictly required for in vitro viral replication (Li et al.,
1998).
S2 expression is not required for in vitro viral replication of
p19/wenv17-derived virus
We next assayed the requirements for S2 protein expression
on the background of p19/wenv17 as we have demonstrated
that virus derived from this plasmid induces severe acute
disease in vivo (Payne et al., 1998), unlike pER-derived virus
that does not induce disease expression in vivo (Whetter et al.,
1990). As retroviruses have been shown to undergo sequence
reversion both in vitro and in vivo, we sought to engineer an
S2 mutant that would require multiple mutations for reversion.
Four mutations were introduced using site-directed mutagen-
esis on the p19/wenv17 background as shown in Fig. 3. We
introduced two deletions at nucleotides 5284 and 5297,
disrupted the AUG start site to AAG at position 5287, and
introduced a noncoding change at position 5292 (Fig. 3).
Mutant constructs were screened by sequence analysis for the
desired changes, and care was taken to insure that plasmid
preparations of p19/wenv17ΔS2 were not contaminated by
low levels of the parental DNA. After transfection of p19/
wenv17ΔS2 plasmid DNA into D17 cells, RT counts were
normalized and cell-free supernatants were used to infect
equine macrophages. Viral growth curves comparing p19/
wenv17-derived virus to p19/wenv17ΔS2-derived are shown
in Fig. 4C. The parental p19/wenv17-derived virus replicates
in vitro only in equine macrophage cells. Low levels of RT
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activities were 70,000 and 90,000 cpm/ml of culture
supernatant for the parental and S2 mutant viruses respective-
ly. This result shows that, on the background of p19/wenv17-
derived virus, the lack of S2 expression has no effect on EIAV
replication in eMDM.
S2 is required for acute disease expression by p19/wenv17
To test whether S2 affects disease expression, two ponies
were inoculated intravenously with 200,000 cpm of macro-
phage-derived virus from p19/wenv17ΔS2. To serve as
controls, two ponies (#30158 and #30159) were inoculatedFig. 4. In vitro virus replication data. Normalized RT counts from transiently
transfectedD17 cells containing either the parent virus pER or the S2mutants p14
and p22 (A) were used to infect equine macrophage cells or equine dermis cells
(B). Virus derived from p19/wenv17 or the mutant virus p19/wenv17ΔS2 was
used to infect equine macrophage cells (C). RT samples were collected and
assayed at the indicated day post-infection.with 200,000 cpm of p19/wenv17-derived parental virus. Fig.
5 compares the clinical course of the disease for the ponies
infected with clone p19/wenv17-derived virus stocks and
ponies infected with p19/wenv17ΔS2-derived virus stocks.
The p19/wenv17-infected ponies experienced severe febrile
episodes with body temperatures reaching 40.5 to 41 °C.
Febrile episodes were accompanied by a significant drop in
platelets (less than 20,000 per microliter at day 16 for both
ponies) to only 10–17% of normal. Following established
animal use protocols, ponies #30158 and #30159 were
humanely euthanized due to the severity of the clinical
symptoms. The development and severity of acute febrile
episodes seen in the control ponies used in this study were
essentially identical to two ponies (#38058 and #29987) that
were previously infected with the same dose of p19/wenv17-
derived virus stock (Payne et al., 1998). In the earlier study,
ponies infected with p19/wenv17-derived virus experienced
febrile episodes (with body temperatures reaching 40.5 to
41C) by 2 weeks post-infection. These animals also
experienced severe thrombocytopenia, with platelet numbers
reduced by as much as 85% from normal levels (Payne et al.,
1998). In stark contrast, the p19/wenv17ΔS2 virus-infected
ponies (#20113 and #422115, Fig. 5) did not experience any
febrile episode or platelet drop within 2 weeks post-infection.
In addition, the animals showed no clinical signs through a
180-day observation period (Fig. 5; insets).
In a previous study (Li et al., 2000), the S2 orf was deleted
on the background of EIAVUK, a clone that produces disease in
approximately 43% of infected animals (Cook et al., 2003).
Ponies infected with 106.0 infectious center doses of an
EIAVUK stock experienced a mild decrease in platelet counts
(an average of 35%), while infection with the related S2 mutant
(EIAVUK2M/X) resulted in an average 12% reduction in platelets
below normal levels (Li et al., 2000). Unfortunately, the
EIAVUK ponies in this study did not experience measurable
febrile episodes. Thus, while deletion of S2 did indeed affect
platelet numbers, the lack of overt disease by the parental clone
did not allow for a rigorous test of the potential impact of S2 on
disease expression. In contrast, our current results dramatically
demonstrate the effect of S2 expression on acute disease
expression, and it can be concluded that the lack of S2
expression alone is sufficient to attenuate a highly virulent
strain of EIAV.
Plasma virus loads
To directly compare the in vivo replication of p19/wenv17-
derived and p19/wenv17ΔS2-derived virus stocks, we used
quantitative PCR (Q-PCR) assays to measure viral RNA loads
from plasma samples. At the 7 dpi time point, when all four
animals had normal body temperatures, ponies infected with
p19/wenv17-derived virus had viral RNA titers of 5.85 and 4.3
logs/ml of plasma. Ponies infected with virus derived from p19/
wenv17ΔS2 had viral RNA titers of 3.3 and 2.85 logs/ml of
plasma. At 15 dpi, the p19/wenv17-infected ponies developed
body temperatures of over 40 °C. Their plasma virus loads were
increased to 9.0 and 7.48 logs/ml of plasma. In contrast, at 16
Fig. 5. Clinical data for ponies infected with virus derived from p19/wenv17 and p19/wenv17ΔS2. Rectal temperatures and complete blood cell counts were monitored
on a daily basis for up to 180 days post-infection.
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maintained normal body temperatures and had viral RNA titers
of 4.9 and 2.78 logs/ml. Overall, virus titers at the 7 dpi time
point averaged 2 logs higher and at the 15–16 dpi time point
averaged 4.4 logs higher for the p19/wenv17-infected ponies.
Cell-associated viral DNA from peripheral blood was also
measured at various days post-infection. Real-time PCR results
of viral DNA in peripheral blood indicated a 5 to 6 logs/ml
DNA titer for p19/wenv17-infected ponies and a 4 to 5 logs/ml
titer for p19/wenvΔS2-infected ponies at 15 dpi. The difference
in proviral DNA titers in peripheral blood (average of 2.5 logs)
was reflective of, but was less dramatic than, differences in free
viral load (average of 4.4 logs) at the day 15–16 post-infection
time point. These results suggest that the differences in plasma
viral loads observed for p19/wenv17- versus p19/wenv17ΔS2-
infected ponies are not solely based on numbers of infected
macrophages.
Previous studies using the EIAVUK (University of Ken-
tucky) strain of EIAV demonstrated that the S2 gene is
required for efficient replication in vivo. The plasma viral load
values we obtained for our S2 mutant are approximately 10- to
50-fold higher than plasma viral loads obtained from the S2
mutant constructed by Li et al., 2000. This may be due to virus
strain differences as average virus loads for EIAVUK averaged
4 to 5 logs during the first 3 weeks pi. Compared to the
EIAVUK parent, infections with the S2 mutant EIAVUK2M/X
resulted in plasma viral RNA loads that differed by less than 1
log from the parental virus for the majority of time points
during the first month post-infection (Li et al., 2000). This is in
contrast to our current report where the virus loads for the
parental and S2 mutant viruses differed by up to 4 logs.
Therefore, our data show a much more dramatic effect of the
S2 mutation on a background of a virus that can replicate tohigh titer at early time points post-infection. In our acute
disease assay system, we were not able to follow the virus
loads at later time points however (as the ponies infected with
parental virus were humanely euthanized during the acute
disease episodes). In the study of Li et al. (2000), the average
viral load in three EIAVUK-infected ponies increased by up to
3 logs over a period of months, while the viral loads in the S2-
mutant-infected ponies failed to increase. One possible
explanation is that EIAVUK parent became better adapted for
optimum growth while the S2 mutant was more severely
constrained.
To ensure that the ponies in our current study were infected
with S2 mutated virus, cycle sequencing was performed on
either the PCR amplifications from the whole blood lysates or
from individual subclones. At 14 dpi, pony #38059 had an S2
sequence identical to the mutant clone as determined by
sequencing of the amplified DNA and three individual clones.
Sequences derived from pony #29987 at 5 dpi (obtained by
sequencing PCR products) were also identical to the original
mutant S2 sequence. Interestingly, sequences obtained from
pony #20113 at 5 months post-infection had reverted back to the
parental S2 amino acid sequence while retaining the noncoding
change designed to mark the mutant virus. We were unable to
detect any sequence changes at 5 months post-infection with
pony #422115. This observation suggests a positive selection
for S2 expression in vivo.
In summary, we present compelling data showing a major
role for S2 expression in the development of acute disease. We
used a highly virulent clone-derived virus (Payne et al., 1998) as
the parent for our S2 mutations. The mutations introduced into
the S2 region abolished detectable S2 expression as determined
by immunoprecipitation assays of infected macrophages. The
abrogation of S2 expression on the p19/wenv17 background
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over 4 logs/ml. Ponies infected with virus derived from p19/
wenv17ΔS2 did not display any clinical signs of disease, in
sharp contrast to ponies infected with p19/wenv-derived virus,
and they remained symptom-free for approximately 6 months.
The ponies were indeed infected with the p19/wenv17ΔS2
mutant, as demonstrated by a virus-specific antibody responses
(data not shown), detection of PCR products from peripheral
blood cells, and viral RNA in plasma samples. Sequence data
obtained at 5 dpi and 14 dpi indicated that no reversion of S2
mutant sequences had occurred within this time frame and this
mutant virus was indeed replicating in vivo.
Our current studies as well as previous reports (Li et al.,
2000, 2003) demonstrated the importance of the S2 gene
product in vivo and illustrate the accessory role of S2 in EIAV
replication. However, these studies do not elucidate the
functional role of S2 in viral pathogenesis. There are a small
number of predicted functional motifs found in S2: GLFG
(yeast nucleoporin motif) (Wente and Blobel, 1994), PXXP
(putative SH3 domain binding motif) (Macdonald et al., 2004),
and two predicted myristylation sites, (GVTWSA and
GGSQGE) that would require a cleavage of the S2 protein
between amino acids 6 and 7 or amino acids 17 and 18 to leave a
C-terminal glycine (Towler et al., 1988). Fig. 1 displays an
alignment of the predicted amino acid sequences of the
available EIAV S2 proteins. It is interesting to note that a
comparison of North American, Japanese, and Chinese virus
strains indicates that not all strains share the putative
nucleoporin motif but all strains share the first myristylation
site, the casein kinase 2 phosphorylation site, the SH3 domain
binding site, and at least two protein kinase C phosphorylation
sites. These results suggest that the conserved myristylation,
SH3-binding, and three kinase sites play important roles in S2
function.
The Nef proteins of HIV and SIV have been studied
extensively and perform a variety of in vitro functions that are
most likely relevant for viral persistence and disease progres-
sion in vivo (reviewed in Arold and Baur, 2001; Schindler et al.,
2004). These functions include down-regulation of CD4, CD3,
CD28, and MHC class I receptors and T-cell activation.
Furthermore, MHC class II antigen presentation is affected by
down-regulation of MHC-II and up-regulation of the invariant
chain that is normally associated with immature MHC-II
receptors. It is suggested that these Nef activities could
indirectly increase viral spread by assisting SIV and HIV in
evading host immune responses as well as by directly enhancing
virus infectivity and production of virus particles. A number of
studies have recently demonstrated that Nef functions can be
mapped to specific sites or motifs located throughout the
molecule (reviewed in Schindler et al., 2004). Although there is
no evidence of significant amino acid homology between the S2
of EIAV and Nef proteins of HIV and SIV, there are a few
common motifs that are shared between these proteins. These
include the myristylation site, the SH3-binding domain (PxxP),
and predicted protein kinase C phosphorylation sites. The
myristylation site is critically important for all SIV Nef
functions, and it has been shown that one protein kinase Cphosphorylation site is important for down-modulation of CD4,
CD8, CD3, MHC-I, and MHC-II receptors (Schindler et al.,
2004). The SH3-binding domain of SIVmac239 is not required
for induction of AIDS in macaques (Carl et al., 2000; Lang et al.,
1997) but, unlike SIV, is required for down-modulation ofMHC-
I, MHC-II, and CD28 in HIV-1 (Greenberg et al., 1998) which
underscores its likely importance in HIV pathogenesis.
Yoon et al., 2000 have expressed the EIAV S2 protein from
the pSPEIAV19 and PV strains of virus in the absence of other
viral proteins in COS, D17, and 293T cells. Their results
indicated punctate cytoplasmic staining of expressed S2
suggestive of an association with subcellular structures. No
nuclear staining was detected, and this distribution was not
altered in the presence of other EIAV proteins. These
investigators detected S2 binding to the p55 gag precursor
protein, although the authors concluded that the S2 protein is
not efficiently packaged into virions. This interaction led the
authors to speculate that S2 could play a role in virus particle
assembly but rules out an early role in virus infection due to a
lack of incorporation into virus particles. The putative motifs of
myristylation, casein kinase II, and protein kinase C phosphor-
ylation and SH3 binding for S2 need further characterization to
determine if they are functional. Perhaps the proposed SH3-
binding domain of S2 is similar to the SH3 domain of HIV nef
and may interact with protein kinases of the Src family affecting
lymphocyte and macrophage signaling pathways (Corey and
Anderson, 1999). Our S2 mutants behave similarly to nef-
deficient virus infections in vivo with infected individuals
experiencing long-term nonprogressive HIV infection and low
virus loads (Deacon et al., 1995; Kirchhoff et al., 1995), but this
would also describe the in vivo phenotypes of vpr and vpx
mutants of SIV as well.
Materials and methods
Cell lines
D17 cells (canine osteosarcoma, ATCC# CRL-8468), ED
(equine dermal cells, ATCC# CCL 57), and Cf2Th (Canine fetal
thymus cells, ATCC# CRL 1430) were cultured in 25-cm2
flasks or 60 mm2 containing Dulbecco's modified Eagle's
medium (DMEM) (Cell-gro) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 2 mM glutamine, and 50
μg/ml gentamicin (GibcoBRL) and maintained at 37 °C with
5% CO2. Equine monocytes were isolated from uninfected
ponies and cultured using a Histopaque-1077 (Sigma) separa-
tion (Targowski, 1976). The monocyte-derived macrophages
were cultured in RPMI 1640 (Cell-gro) supplemented with 10%
autologous horse serum, 2 mM glutamine, 2 mM sodium
pyruvate, and 50 μg/ml gentamicin and maintained at 37 °C
with 5% CO2.
Mutagenesis and construction of plasmids (S2 mutants on pER
[CL22] genetic background)
Two different infectious clones harboring termination
codons in two different locations were constructed (see Fig.
28 A.J. Fagerness et al. / Virology 349 (2006) 22–302A). Mutations were made by primer-directed sequence
modification with PCR amplification using the EIAV infectious
molecular clone pER (Perry et al., 1992) as the template. The
recombinant PCR was performed by first generating two
separate PCR amplifications; one reaction contained an
upstream S2 mutagenesis primer and a downstream bEcoR1-
envB primer (5′-GCCAATTCGTATGATTTTGTACTTC-
CATTA-3′), the second reaction contained the upstream primer
R1-polDN (5′-GCGAATTCGATATGTGGTAATCAATTGG-
3′) paired with a downstream S2 mutagenesis primer. The S2
mutagenesis primers for the p14 (S2-5301) clone were S2-
5287N (5′-TGGGATTATTTGGTTAGGGGGTAACATGGT-3′)
and bS2-5316 (5′-ACCATGTTACCCCCTAACAATAAT-
CCCA-3′). The primers used for p22 (S2-5323), the second S2
mutant generated, were S2-5310N (5′-ACATGGTCAGCATAG-
CATTCTATGGGGGGA-3′) and bS2-5339 (5′-TCCCCCCA-
TAGAATGCTATGCTGACCATGT-3′). Each of the initial 100
μl reactions contained 10 mM Tris–HCl (pH 9.0), 50 mM KCl,
0.1% Triton X-100, 1.5 mM MgCl2, 200 μM of each dNTP, 1.0
μMof each primer, 2.5 U of AmpliTaq DNA polymerase (Perkin
Elmer Cetus), and 5 ng of plasmid DNA. After 30 cycles of
amplification were completed, the reactions were centrifuged
through a chromaspin 100 column (Clonetech) to remove the
primers. The two reactions were combined, and 3 μl was used for
the final PCR amplification. This reaction generated a 2.9 kb
fragment containing the desired S2 mutation using the EcoR1-
polDN primer with the bEcoR1-envB primer. This final PCR
product was digested with EcoR1 and ligated into an EcoR1-
digested, dephosphorylated pLG338-ApR subcloning vector
(Cunningham et al., 1993). From this subclone, anNheI fragment
(nt 3910 to 6700) was excised and ligated to NheI-digested,
dephosphorylated pER(-)Nhe.
Mutagenesis and construction of plasmids (S2 mutants on
virulent, infectious molecular clone [p19/wenv17] genetic
background)
Four nucleotide changes were introduced in the S2 coding
region of p19/wenv17 to generate the infectious molecular clone
p19/wenv17ΔS2 (see Fig. 3). These changes were performed
using site-directed mutagenesis (Stratagene). The upstream
oligonucleotide was 5′-GATTAAGGGATTATTGGTAA-
AGGGGTAACATGG-3′, and the downstream oligonucleotide
was 5′-CCATGTTACCCCTTTACCAATAATCCCTTAATC-
3′. The 50 μl reactions contained 200 ng of template DNA
(p19/wenv17), 1.25 μM of each primer, 50 μM dNTPs, reaction
buffer, and Pfu thermostabile DNA polymerase (2.5 units). The
cycling parameters were: 95 °C for 30 s for 1 cycle; 95 °C for
30 s, 55 °C for 30 s, 68 °C for 35 s for 25 cycles. Following
the cycling, the samples were placed on ice for 2 min and then
incubated at 37 °C with restriction endonuclease DpnI for 3 h.
Approximately 1 ng of the reaction was used to transform 100
μl of E. coli DH5α′ competent cells (GibcoBRL). Approx-
imately 200 μl of the transformation was plated on LB agar
plates that contained 20 mg/ml of ampicillin. After 24 h of
growth at 37 °C, colonies were picked and grown in 3 ml
Luria broth (LB) supplemented with ampicillin. Sixteen hourslater, minipreps (Qiagen) were performed. DNA from the
minipreps was sequenced via cycle sequencing (Promega) to
check for desired changes. Mutant colonies were streaked 3
times for isolated colonies to ensure a pure culture and were
then re-sequenced.
Transfections and infections
Virus stocks were obtained by transfecting D17 cells (for
p19/wenv17 and p19/wenv17ΔS2) or Cf2Th cells (for pER
derivatives) using the calcium phosphate precipitation method
(Gibco/Life Technologies) as we have previously described
(Threadgill et al., 1993). The transfected cell supernatants were
then normalized for reverse transcriptase (RT) activity (see
below), and 20,000 cpm/ml was used to infect macrophages that
had been established for 24 h. Approximately 200,000 cpm of
macrophage supernatant (as determined by RT assay) of p19/
wenv17ΔS2 macrophage-derived cell culture supernatant was
used to infect 2 ponies. Reverse transcriptase assays were
performed as we have previously described (Steagall et al.,
1995).
Clinical assays
Pony rectal temperatures and blood cell counts were
monitored on a daily basis both pre- and post-infection.
Temperature and platelet counts were plotted as a function of
time up to 180 days post-infection (dpi).
Immunoprecipitations
Equine macrophages in 60 mm dishes were infected with
virus derived from pER or the S2 mutants (100,000 cpm RT
activity) and radiolabeled at 7 dpi with Cys–Met-free RPMI
containing 100 μCi/ml 35S-cysteine and 35S-methionine
Translabel (ICN Radiochemicals Inc.) for 10 h. Immuno-
precipitations were performed as described by Springer
(1996). The solubilized proteins were resolved by electro-
phoresis on a 15% polyacrylamide-SDS gel. After electro-
phoresis, the gel was treated with EN3HANCE (DuPont) for
autoradiographic enhancement and exposed to X-ray film at
−70 °C.
Quantitative PCR Assays of vRNA and proviral DNA
Viral RNA loads from plasma were determined by extraction
of 200 μl of plasma by use of the High Pure Viral Nucleic Acid
Kit (Roche) and elution of vRNA in 50 μl of elution buffer. A
10 μl RNA aliquot was added to a reverse transcription mix
containing a final concentration of 1× reaction buffer, 2.5 mM
MgCl2, 0.7 mM dNTPs, 0.8 units of RNase inhibitor, 2 μM
random hexamers, and 2 units of MuLV reverse transcriptase
from the GeneAmp RNA PCR kit (Applied Biosystems). After
incubation for 5 min at room temperature, the mix was placed at
42 °C for 15 min and then 99 °C for 5 min to inactivate the
reverse transcriptase. A 12.5 μl aliquot of the cDNAwas used as
template for a Quantitative PCR assay. The PCR reaction mix
29A.J. Fagerness et al. / Virology 349 (2006) 22–30(50 μl) contained a final concentration of 1× reaction buffer, 3.5
mM MgCl2, 0.2 mM dNTPs (each), 0.2 mM upstream primer
(5′-TTCCCATGACAGCAAGGTTT-3′), 0.2 mM downstream
primer (5′-TCCATTGTCTATATGTCTGCCTAAA-3′), 0.05
mM Taqman probe (5′-FAM-CAAAAGCAGGCTCCATCT-
GTCTTTCTCTAGGACT-TAMRA-3′), and 1.25 units of
AmpliTaq Gold polymerase (Applied Biosystems). Cycling
parameters were 95 °C for 30 s and 60 °C for 1 min (45
cycles). DNA standards consisted of p19/wenv17 plasmid
DNA at 101–107 copies per reaction in a 10-fold serial
dilution. Real-time PCR was performed using BioRad Icycler
and Icycler software for data analysis. Proviral DNA was also
analyzed using whole blood cellular lysates obtained from the
infected ponies at various time points and prepared as
described (Perry et al., 1992). Quantitative PCR analysis was
performed essentially as described above, without the initial
reverse transcriptase step.
Sequencing analysis
RT-PCR products generated for virus quantitation (as
described above) were sequenced directly (Cycle sequencing,
Promega). Prior to sequencing, 200 ng of PCR product was
treated with 2 U of exonuclease I and 2 U of shrimp alkaline
phosphatase and heated to 37 °C for 15 min followed by 80 °C
for 15 min. The inactivated product was combined with 2 μl of a
10 μM stock of an internal primer b5395 5′-GATTTTTCT-
GACTGTTGGG-3′, 0.5 μCi of dATP 32P, 5 μl of 5× sequencing
buffer. In addition to directly sequencing PCR products, some
reactions were cloned into pGEM (3Z) (Promega). Colonies
were screened by restriction enzyme analysis followed by Cycle
sequencing.
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